| Code | 2829D | ||||||||||
| MA number | 21/0157/05-S | ||||||||||
| Product Form: | cps dur 200(2x100)x300 mg (blis.PVC/PVDC/Al-multibal.) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | Teva B.V., Netherland | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | blister PVC/PVDC/Al | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10c informed consent application |
| MA issued: | 09.06.2005 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| PIL: |
PIL_Gabapentin Teva_cps dur_07.2024.pdf
|
| SPC: |
SPC_Gabapentin Teva_cps dur_09.2024.pdf
|
| Safety feature | Yes |
| Data update: | 13.09.2024 |
